Literature DB >> 26475285

Denosumab after 8 years.

I R Reid1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26475285     DOI: 10.1007/s00198-015-3347-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  16 in total

1.  Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

Authors:  Ian R Reid; Paul D Miller; Jacques P Brown; David L Kendler; Astrid Fahrleitner-Pammer; Ivo Valter; Katre Maasalu; Michael A Bolognese; Grattan Woodson; Henry Bone; Beiying Ding; Rachel B Wagman; Javier San Martin; Michael S Ominsky; David W Dempster
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

2.  Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Michael Gnant; Georg Pfeiler; Peter C Dubsky; Michael Hubalek; Richard Greil; Raimund Jakesz; Viktor Wette; Marija Balic; Ferdinand Haslbauer; Elisabeth Melbinger; Vesna Bjelic-Radisic; Silvia Artner-Matuschek; Florian Fitzal; Christian Marth; Paul Sevelda; Brigitte Mlineritsch; Günther G Steger; Diether Manfreda; Ruth Exner; Daniel Egle; Jonas Bergh; Franz Kainberger; Susan Talbot; Douglas Warner; Christian Fesl; Christian F Singer
Journal:  Lancet       Date:  2015-05-31       Impact factor: 79.321

3.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

4.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

5.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

6.  The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Jane A Cauley; Felicia Cosman; Ping Chung Leung; Peter Lakatos; Kurt Lippuner; Steven R Cummings; Trisha F Hue; Amitava Mukhopadhyay; Monique Tan; R Paul Aftring; Richard Eastell
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

7.  The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

8.  The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.

Authors:  S Papapoulos; K Lippuner; C Roux; C J F Lin; D L Kendler; E M Lewiecki; M L Brandi; E Czerwiński; E Franek; P Lakatos; C Mautalen; S Minisola; J Y Reginster; S Jensen; N S Daizadeh; A Wang; M Gavin; C Libanati; R B Wagman; H G Bone
Journal:  Osteoporos Int       Date:  2015-07-23       Impact factor: 4.507

9.  Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.

Authors:  S Ferrari; J D Adachi; K Lippuner; C Zapalowski; P D Miller; J-Y Reginster; O Törring; D L Kendler; N S Daizadeh; A Wang; C D O'Malley; R B Wagman; C Libanati; E M Lewiecki
Journal:  Osteoporos Int       Date:  2015-06-12       Impact factor: 4.507

10.  Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?

Authors:  Felicia Cosman; Jane A Cauley; Richard Eastell; Steven Boonen; Lisa Palermo; Ian R Reid; Steven R Cummings; Dennis M Black
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

View more
  1 in total

Review 1.  Osteocytic signalling pathways as therapeutic targets for bone fragility.

Authors:  Lilian I Plotkin; Teresita Bellido
Journal:  Nat Rev Endocrinol       Date:  2016-05-27       Impact factor: 43.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.